

**CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2016**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 201532	15	New Indication	ERIBULIN MESYLATE	EISAI INC	P	7/29/2015	1/28/2016	6.0
NDA 022334	32	Accelerated Approval Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	S	3/31/2015	1/29/2016	10.0
NDA 203985	10	Accelerated Approval Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	S	3/31/2015	1/29/2016	10.0
NDA 022023	6	New Dosing Regimen		MERCK SHARP AND DOHME CORP	S	7/30/2015	2/1/2016	6.1
NDA 022056	18	Pediatric		ASTRAZENECA PHARMACEUTICALS LP	S	4/3/2015	2/3/2016	10.1
NDA 206843	1	New Indication	DACLATASVIR	BRISTOL-MYERS SQUIBB CO	P	8/5/2015	2/5/2016	6.0
NDA 206843	2	New Indication	DACLATASVIR	BRISTOL-MYERS SQUIBB CO	P	8/5/2015	2/5/2016	6.0
NDA 206843	3	New Indication	DACLATASVIR	BRISTOL-MYERS SQUIBB CO	P	8/5/2015	2/5/2016	6.0
NDA 205029	2	New Indication		BELCHER PHARMACEUTICALS LLC	S	4/15/2015	2/11/2016	9.9
NDA 205834	7	New Patient Population	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	8/26/2015	2/12/2016	5.6
NDA 205834	8	New Indication	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	8/26/2015	2/12/2016	5.6
NDA 205834	9	New Patient Population	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	8/26/2015	2/12/2016	5.6
NDA 022334	35	Accelerated Approval Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	P	8/24/2015	2/18/2016	5.9
NDA 207103	2	New Indication		PFIZER INC	P	10/15/2015	2/19/2016	4.2
NDA 202123	21	New Patient Population		GILEAD SCIENCES INC	S	4/23/2015	2/23/2016	10.1
NDA 205382	2	New Indication		GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND	S	4/28/2015	2/24/2016	9.9
NDA 022334	36	New Indication		NOVARTIS PHARMACEUTICALS CORP	P	8/27/2015	2/26/2016	6.0
NDA 205123	10	New Patient Population		JANSSEN PRODUCTS LP	S	4/30/2015	2/26/2016	9.9
NDA 021752	47	New Patient Population		GILEAD SCIENCES INC	S	5/13/2015	3/10/2016	9.9
NDA 202570	16	New Indication		PF PRISM CV	P	10/8/2015	3/11/2016	5.1
NDA 022159	11	New Patient Population		SEPTODONT HOLDING SAS	S	5/19/2015	3/18/2016	10.0
NDA 020687	20	New Dosing Regimen		DANCO LABORATORIES LLC	S	5/29/2015	3/29/2016	10.0
NDA 203684	1	New Indication		BRACCO DIAGNOSTICS INC	S	6/4/2015	3/31/2016	9.9
NDA 201292	7	New Indication		BOEHRINGER INGELHEIM	S	6/16/2015	4/15/2016	10.0
NDA 205122 (1)	3	New Indication	TOPIRAMATE EXTENDED RELEASE CAPSULES	UPSHER-SMITH LABORATORIES INC	S	6/17/2015	4/15/2016	10.0
NDA 206619	9	New Dosing Regimen		ABBVIE INC	P	10/27/2015	4/22/2016	5.9
NDA 201277	11	New Indication		BAYER HEALTHCARE PHARMACEUTICALS INC	S	6/30/2015	4/27/2016	9.9
NDA 205636	4	New Patient Population		TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC	S	6/29/2015	4/28/2016	10.0
NDA 021324	12	New Patient Population		PERRIGO PHARMA INTERNATIONAL DAC	S	6/30/2015	4/29/2016	10.0

CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2016

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

NDA 021324	13	New Patient Population	PERRIGO PHARMA INTERNATIONAL DAC	S	6/30/2015	4/29/2016	10.0
NDA 205552	10	New Indication	PHARMACYCLICS LLC	P	11/12/2015	5/6/2016	5.8
NDA 205552	13	New Indication	PHARMACYCLICS LLC	P	11/12/2015	5/6/2016	5.8
NDA 021116	16		LLOYD INC	S	7/16/2015	5/19/2016	10.1
NDA 021743	23	New Dosing Regimen	OSI PHARMACEUTICALS LLC	S	7/21/2015	5/20/2016	10.0
NDA 050795	22	New Dosing Regimen	MAYNE PHARMA INTERNATIONAL PTY LTD	S	7/20/2015	5/20/2016	10.0
NDA 204353	6	New Indication	JANSSEN PHARMACEUTICALS INC	S	7/20/2015	5/20/2016	10.0
NDA 021366	33	New Indication	IPR PHARMACEUTICALS INC	S	7/27/2015	5/27/2016	10.0
NDA 200327	16	New Patient Population	CEREXA INC	P	12/7/2015	5/27/2016	5.7
NDA 200327	17	New Patient Population	CEREXA INC	P	12/7/2015	5/27/2016	5.7
NDA 204790	8	New Patient Population	VIIV HEALTHCARE CO	P	12/9/2015	6/9/2016	6.0
NDA 202895	17	New Patient Population	JANSSEN PRODUCTS LP	P	12/17/2015	6/17/2016	6.0
NDA 020380	10	Rx To OTC Switch	GALDERMA LABORATORIES LP	S	9/10/2015	7/8/2016	9.9
NDA 022287	21	New Indication	TAKEDA PHARMACEUTICALS USA INC	S	9/30/2015	7/8/2016	9.3
NDA 022287	22	New Indication	TAKEDA PHARMACEUTICALS USA INC	S	9/30/2015	7/8/2016	9.3
NDA 022287	23	New Indication	TAKEDA PHARMACEUTICALS USA INC	S	9/30/2015	7/8/2016	9.3
NDA 206111	1	New Indication	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	9/11/2015	7/8/2016	9.9
NDA 208056	1	New Patient Population	TAKEDA PHARMACEUTICALS USA INC	S	1/29/2016	7/8/2016	5.3
NDA 012209	40	New Dosing Regimen	SPECTRUM PHARMACEUTICALS INC	U	12/26/2013	7/29/2016	31.1
NDA 022051	13	Rx To OTC Switch	GLAXOSMITHKLINE	S	10/2/2015	8/2/2016	10.0
NDA 201635 (1)	11	New Indication	SUPERNUS PHARMACEUTICALS INC	S	6/21/2016	8/18/2016	1.9
NDA 201635	14	New Patient Population	SUPERNUS PHARMACEUTICALS INC	S	6/21/2016	8/18/2016	1.9
NDA 021252	14	New Patient Population	FOREST LABORATORIES LLC	P	3/11/2016	9/2/2016	5.8
NDA 021710	11	New Indication	VALIDUS PHARMACEUTICALS INC	S	3/25/2016	9/23/2016	6.0
NDA 021710	12	New Indication	VALIDUS PHARMACEUTICALS INC	S	3/25/2016	9/23/2016	6.0
NDA 206038	5	New Patient Population	VERTEX PHARMACEUTICALS INC	P	3/30/2016	9/28/2016	6.0
NDA 204242	7	Manufacturing Change With Clinical Data	OREXO US INC	S	12/4/2015	10/4/2016	10.0
NDA 021560	19	New Indication	NOVARTIS PHARMACEUTICALS CORP	S	12/16/2015	10/12/2016	9.9
NDA 021606	16	New Patient Population	ABBVIE INC	S	12/18/2015	10/18/2016	10.0
NDA 021606	17	New Patient Population	ABBVIE INC	S	12/18/2015	10/18/2016	10.0
NDA 021743	25	New Indication	OSI PHARMACEUTICALS LLC	S	12/18/2015	10/18/2016	10.0
NDA 022128	17	New Patient Population	VIIV HEALTHCARE CO	P	5/6/2016	11/4/2016	6.0
NDA 019599	13	New Patient Population	SEBELA IRELAND LTD	S	1/13/2016	11/10/2016	9.9
NDA 203469	22	Accelerated Approval Confirmatory Study	ARIAD PHARMACEUTICALS INC	S	2/12/2016	11/28/2016	9.5
NDA 204629	8	New Indication	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	11/4/2015	12/2/2016	13.0
NDA 203313	2	New Patient Population	NOVO NORDISK INC	S	2/16/2016	12/16/2016	10.0
NDA 203314	3	New Patient Population	NOVO NORDISK INC	S	2/16/2016	12/16/2016	10.0

**CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2016**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

NDA 203684	2	New Indication		BRACCO DIAGNOSTICS INC	P	6/29/2016	12/22/2016	5.8
NDA 206111	4	New Indication		BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	12/4/2015	12/23/2016	12.7
NDA 208658	1	New Indication		BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	12/12/2016	12/23/2016	0.4

NDA Efficacy Supplements Approved (SE8)

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 021883	3	Labeling Change With Clinical Data		DURATA THERAPEUTICS INTERNATIONAL BV	P	7/20/2015	1/20/2016	6.0
NDA 202714	10	Labeling Change With Clinical Data	CARFILZOMIB	ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC	P	7/22/2015	1/21/2016	6.0
NDA 203496	2	Labeling Change With Clinical Data	TREPROSTINIL	UNITED THERAPEUTICS CORP	S	3/31/2015	1/28/2016	10.0
NDA 206229	1	Labeling Change With Clinical Data	LEVONORGESTREL RELEASING IUS	MEDICINES360	S	4/1/2015	1/29/2016	10.0
NDA 021344	26	Labeling Change With Clinical Data		ASTRAZENECA PHARMACEUTICALS LP	S	11/17/2015	3/2/2016	3.5
NDA 205552	7	Labeling Change With Clinical Data		PHARMACYCLICS LLC	P	9/10/2015	3/4/2016	5.8
NDA 202192	12	Labeling Change With Clinical Data		INCYTE CORP	S	6/17/2015	3/10/2016	8.8
NDA 204629	5	Labeling Change With Clinical Data		BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	5/20/2015	3/18/2016	10.0
NDA 206756	2	Labeling Change With Clinical Data		BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	5/29/2015	3/18/2016	9.7
NDA 022271	5	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	12/6/2013	4/5/2016	28.0
NDA 022350	14	Labeling Change With Clinical Data		ASTRAZENECA AB	S	2/28/2014	4/5/2016	25.2
NDA 022426	3	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	12/6/2013	4/5/2016	28.0
NDA 200678	13	Labeling Change With Clinical Data		ASTRAZENECA AB	S	2/28/2014	4/5/2016	25.2
NDA 203414	3	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	12/6/2013	4/5/2016	28.0
NDA 205551	5	Labeling Change With Clinical Data		VIIV HEALTHCARE CO	S	6/24/2015	4/21/2016	9.9

**CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2016**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

NDA 022341	25	Labeling Change With Clinical Data		NOVO NORDISK INC	S	6/23/2015	4/22/2016	10.0
NDA 204790	7	Labeling Change With Clinical Data		VIIV HEALTHCARE CO	S	6/24/2015	4/22/2016	10.0
NDA 022110	12	Labeling Change With Clinical Data		THERAVANCE BIOPHARMA ANTIBIOTICS INC	S	7/7/2015	5/6/2016	10.0
NDA 202439	17	Labeling Change With Clinical Data	RIVAROXABAN	JANSSEN PHARMACEUTICALS INC	S	7/13/2015	5/6/2016	9.8
NDA 206947	3	Labeling Change With Clinical Data		EISAI INC	P	11/16/2015	5/13/2016	5.9
NDA 203756	2	Labeling Change With Clinical Data		EXELIXIS INC	S	7/20/2015	5/20/2016	10.0
NDA 204042	15	Labeling Change With Clinical Data		JANSSEN PHARMACEUTICALS INC	S	7/20/2015	5/20/2016	10.0
NDA 205123	11	Labeling Change With Clinical Data		JANSSEN PRODUCTS LP	S	7/23/2015	5/20/2016	9.9
NDA 022192	15	Labeling Change With Clinical Data		VANDA PHARMACEUTICALS INC	S	7/27/2015	5/26/2016	10.0
NDA 021743	27	Labeling Change With Clinical Data		OSI PHARMACEUTICALS LLC	S	3/30/2016	6/1/2016	2.1
NDA 203469	21	Labeling Change With Clinical Data		ARIAD PHARMACEUTICALS INC	S	10/16/2015	6/2/2016	7.6
NDA 021976	43	Labeling Change With Clinical Data		JANSSEN PRODUCTS LP	P	12/17/2015	6/17/2016	6.0
NDA 206494	2	Labeling Change With Clinical Data		CEREXA INC	P	12/22/2015	6/22/2016	6.0
NDA 022307	14	Labeling Change With Clinical Data		ELI LILLY AND CO	P	1/12/2016	7/12/2016	6.0
NDA 022518	19	Labeling Change With Clinical Data		MERCK SHARP AND DOHME CORP	S	9/24/2015	7/12/2016	9.6
NDA 205641	5	Labeling Change With Clinical Data		MERCK SHARP AND DOHME CORP	S	9/24/2015	7/12/2016	9.6
NDA 206439	3	Labeling Change With Clinical Data		FOREST LABORATORIES LLC	S	9/18/2015	7/18/2016	10.0
NDA 020564	36	Labeling Change With Clinical Data		VIIV HEALTHCARE CO	P	1/20/2016	7/20/2016	6.0
NDA 020596	35	Labeling Change With Clinical Data		VIIV HEALTHCARE CO	P	1/20/2016	7/20/2016	6.0
NDA 020753	18	Labeling Change With Clinical Data		PHARMACIA AND UPJOHN CO	S	11/20/2015	7/25/2016	8.2
NDA 021928	39	Labeling Change With Clinical Data		PFIZER INC	S	10/13/2015	8/12/2016	10.0
NDA 021588	45	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	S	2/5/2016	8/25/2016	6.6

**CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2016**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

NDA 202429	9	Labeling Change With Clinical Data		HOFFMANN-LA ROCHE INC	S	11/6/2015	8/31/2016	9.8
NDA 207561	1	Labeling Change With Clinical Data		GILEAD SCIENCES INC	S	11/13/2015	9/7/2016	9.8
NDA 203284	4	Labeling Change With Clinical Data		HORIZON THERAPEUTICS INC	S	11/19/2015	9/8/2016	9.7
NDA 206628	2	Labeling Change With Clinical Data		HQ SPECIALTY PHARMA CORP	S	11/19/2015	9/19/2016	10.0
NDA 205422	1	Labeling Change With Clinical Data		OTSUKA PHARMACEUTICAL CO LTD	S	11/23/2015	9/23/2016	10.0
NDA 021085	61	Labeling Change With Clinical Data	MOXIFLOXACIN HYDROCHLORIDE	BAYER HEALTHCARE PHARMACEUTICALS INC	P	9/11/2015	9/27/2016	12.6
NDA 021277	57	Labeling Change With Clinical Data		BAYER HEALTHCARE PHARMACEUTICALS INC	P	9/11/2015	9/27/2016	12.6
NDA 021187	27	Labeling Change With Clinical Data		ORGANON USA INC	S	12/2/2015	9/30/2016	10.0
NDA 021977	41	Labeling Change With Clinical Data		SHIRE DEVELOPMENT LLC	S	12/14/2015	10/14/2016	10.0
NDA 203415	9	Labeling Change With Clinical Data		ASTELLAS PHARMA US INC	S	12/22/2015	10/20/2016	10.0
NDA 022363	11	Labeling Change With Clinical Data		KOWA CO LTD	S	10/26/2015	11/18/2016	12.8
NDA 022127	15	Labeling Change With Clinical Data		GENZYME CORP	P	5/26/2016	11/25/2016	6.0
NDA 022318	8	Labeling Change With Clinical Data		GENZYME CORP	P	5/26/2016	11/25/2016	6.0
NDA 207561	2	Labeling Change With Clinical Data		GILEAD SCIENCES INC	S	11/13/2015	12/7/2016	12.8
NDA 021073	48	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	7/30/2015	12/12/2016	16.5
NDA 021842	20	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	7/30/2015	12/12/2016	16.5
NDA 021925	16	Labeling Change With Clinical Data	PIOGLITAZONE AND GLIMEPIRIDE	TAKEDA PHARMACEUTICALS USA INC	S	7/30/2015	12/12/2016	16.5
NDA 022024	12	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	7/30/2015	12/12/2016	16.5
NDA 022426	6	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	S	7/30/2015	12/12/2016	16.5
NDA 021928	40	Labeling Change With Clinical Data		PFIZER INC	S	2/18/2016	12/16/2016	9.9
NDA 022458	13	Labeling Change With Clinical Data		PFIZER INC	S	2/24/2016	12/20/2016	9.9
NDA 021446	32	Labeling Change With Clinical Data		PF PRISM CV	S	2/29/2016	12/22/2016	9.8

CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2016

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

NDA 022488	11	Labeling Change With Clinical Data	PREGABALIN	PF PRISM CV	S	2/29/2016	12/22/2016	9.8
NDA 206073	7	Labeling Change With Clinical Data		BOEHRINGER INGELHEIM	S	3/4/2016	12/23/2016	9.7

BLA Efficacy Supplements Approved

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE	PROPER NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
BLA 125504	1	COSENTYX	SECUKINUMAB	NOVARTIS PHARMACEUTICALS CORPORATION	S	3/18/2015	1/15/2016	10.0
BLA 125504	2	COSENTYX	SECUKINUMAB	NOVARTIS PHARMACEUTICALS CORPORATION	S	3/23/2015	1/15/2016	9.8
BLA 125326	62	ARZERRA	OFATUMUMAB	NOVARTIS PHARMACEUTICALS CORPORATION	P	7/22/2015	1/19/2016	6.0
BLA 103000	5252	BOTOX	ONABOTULINUMTOXINA	ALLERGAN, INC.	S	7/21/2015	1/21/2016	6.0
BLA 125554	7	OPDIVO	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	7/23/2015	1/23/2016	6.0
BLA 103000	5294	BOTOX® AND BOTOX® COSMETIC (ONABOTULINUMTOXINA)		ALLERGAN, INC.	S	9/23/2015	2/4/2016	4.4
BLA 125486	13	GAZYVA	OBINUTUZUMAB	GENENTECH, INC.	P	8/28/2015	2/26/2016	6.0
BLA 125554	19	OPDIVO	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	3/1/2016	5/17/2016	2.5
BLA 125118	200	ORENCIA®		BRISTOL-MYERS SQUIBB COMPANY	S	8/7/2015	6/7/2016	10.0
BLA 125057	397	ADALINUMAB/HUMIRA	ADALINUMAB/HUMIRA	ABBVIE INC.	S	9/3/2015	6/30/2016	9.9
BLA 103976	5225	XOLAIR® (OMALIZUMAB)		GENENTECH, INC.	S	12/22/2015	7/6/2016	6.5
BLA 125522	1	EVOLOCUMAB		AMGEN, INC.	S	9/10/2015	7/8/2016	9.9
BLA 125522	1	REPATHA (EVOLOCUMAB)		AMGEN, INC.	S	9/10/2015	7/8/2016	9.9
BLA 125319	84	ILARIS® (CANAKINUMAB)		NOVARTIS PHARMACEUTICALS CORPORATION	S	9/22/2015	7/21/2016	10.0
BLA 125274	105	DYSPORT® (ABOBOTULINUMTOXINA)		IPSEN BIOPHARM LIMITED	C	9/30/2015	7/29/2016	10.0
BLA 125514	9	KEYTRUDA®		MERCK SHARP & DOHME CORP.	P	2/9/2016	8/5/2016	5.9
BLA 125326	63	ARZERRA	Ofatumumab	NOVARTIS PHARMACEUTICALS CORPORATION	P	3/10/2016	8/30/2016	5.7
BLA 125557	5	BLINCYTO® (BLINATUMOMAB)		AMGEN, INC.	P	3/1/2016	8/30/2016	6.0
BLA 125554	17	OPDIVO® (NIVOLUMAB)		BRISTOL-MYERS SQUIBB COMPANY	S	2/5/2016	9/13/2016	7.3
BLA 125554	18	OPDIVO® (NIVOLUMAB)		BRISTOL-MYERS SQUIBB COMPANY	S	2/12/2016	9/13/2016	7.0
BLA 125276	107	ACTEMRA®		GENENTECH, INC.	S	11/24/2015	9/23/2016	10.0

**CY 2016 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2016**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2016 End Date: 12/31/2016

Sort Order: Approval Date

BLA 125319	85	ILARIS® (CANAKINUMAB)		NOVARTIS PHARMACEUTICALS CORPORATION	P	3/23/2016	9/23/2016	6.0
BLA 125319	86	ILARIS® (CANAKINUMAB)		NOVARTIS PHARMACEUTICALS CORPORATION	P	3/28/2016	9/23/2016	5.9
BLA 125319	87	ILARIS® (CANAKINUMAB)		NOVARTIS PHARMACEUTICALS CORPORATION	P	3/29/2016	9/23/2016	5.9
BLA 125472	18	ACTEMRA®		GENENTECH, INC.	S	11/24/2015	9/23/2016	10.0
BLA 103780	5196	REBIF® (INTERFERON BETA-1A)		EMD SERONO, INC.	S	11/27/2015	9/27/2016	10.0
BLA 125554	16	OPDIVO® (NIVOLUMAB)		BRISTOL-MYERS SQUIBB COMPANY	S	12/7/2015	10/4/2016	9.9
BLA 761041	1	TECENTRIQ™ (ATEZOLIZUMAB)		GENENTECH, INC.	P	2/19/2016	10/18/2016	8.0
BLA 125514	8	KEYTRUDA® (PEMBROLIZUMAB)		MERCK SHARP & DOHME CORP.	S	12/24/2015	10/24/2016	10.0
BLA 125514	12	KEYTRUDA® (PEMBROLIZUMAB)		MERCK SHARP & DOHME CORP.	P	6/24/2016	10/24/2016	4.0
BLA 103795	5552	ENBREL® (ETANERCEPT)		IMMUNEX CORPORATION	S	1/5/2016	11/4/2016	10.0
BLA 125554	22	OPDIVO® (NIVOLUMAB)		BRISTOL-MYERS SQUIBB COMPANY	P	5/11/2016	11/10/2016	6.0
BLA 761036	3	DARZALEX® (DARATUMUMAB)		JANSSEN BIOTECH, INC.	P	8/17/2016	11/21/2016	3.2
BLA 761036	4	DARZALEX® (DARATUMUMAB)		JANSSEN BIOTECH, INC.	P	8/17/2016	11/21/2016	3.2
BLA 125085	317	AVASTIN® (BEVACIZUMAB)		GENENTECH, INC.	P	6/24/2016	12/6/2016	5.4
BLA 125274	107	DYSPORT® (ABOBOTULINUMTOXINA)		IPSEN BIOPHARM LIMITED	S	3/2/2016	12/9/2016	9.3